At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany, explains that the treatment of metastatic melanoma has been revolutionised by recent developments in immunotherapeutic agents, including ipilimumab, an anti-CTLA-4 antibody, pembrolizumab, an anti-PD-1 antibody, and nivolumab, an anti-PD-1 antibody; targeted agents, including vemurafenib and dabrafenib, both BRAF inhibitors; and the oncolytic virus immunotherapy, talimogene laherparepvec (T-VEC).
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement